Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05085834 · ClinicalTrials.gov registry record · Early Phase 1
Zinc Effect on Inflammation and Cardiovascular Risk in HIV
A Early Phase 1 study, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 95
- Enrollment target
NCT05085834 is a Early Phase 1 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 95 participants.
The verdict
NCT05085834, a Early Phase 1 study, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
To study the effect of short-term zinc supplementation on improving inflammation, metabolic, and cardiovascular risk among HIV infected patients on stable anti-retroviral therapy
Interventions
- DRUG Placebo
- DRUG Zinc Gluconate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2024-08-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05085834
The ClinicalTrials.gov registry entry for NCT05085834 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05085834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05085834 about?
NCT05085834 is a clinical study titled "Zinc Effect on Inflammation and Cardiovascular Risk in HIV". To study the effect of short-term zinc supplementation on improving inflammation, metabolic, and cardiovascular risk among HIV infected patients on stable anti-retroviral therapy
What is the current status of trial NCT05085834?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 95 participants. The study started on 2020-01-22. Estimated completion is 2024-08-02.
What interventions are being tested in trial NCT05085834?
The interventions under investigation include: Placebo (DRUG), Zinc Gluconate (DRUG).
Who is sponsoring clinical trial NCT05085834?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.